Welcome to our dedicated page for Pulse Biosciences news (Ticker: PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.
Pulse Biosciences Inc (NASDAQ: PLSE) pioneers bioelectric medicine through its proprietary Nano-Pulse Stimulation technology, offering investors and medical professionals a novel approach to non-thermal therapies. This dedicated news hub provides real-time updates on clinical advancements, regulatory developments, and strategic partnerships shaping the future of targeted cellular treatments.
Access verified information about PLSE's progress in immuno-oncology applications, dermatology research breakthroughs, and system commercialization efforts. Our curated feed includes earnings reports, FDA submissions, peer-reviewed study results, and executive commentary – all essential for evaluating the company's position in the electroceuticals market.
Key updates cover therapeutic trial milestones, intellectual property expansions, and collaborations with leading medical institutions. Bookmark this page to monitor how PLSE's drug-free energy modalities could transform treatment protocols for complex conditions while driving long-term value in the medical device sector.
Pulse Biosciences (Nasdaq: PLSE) has received FDA clearance for its CellFX® System, designed for dermatologic procedures that require skin ablation and resurfacing. This marks a significant step in the company’s regulatory strategy, following its recent CE mark acquisition. The CellFX System utilizes innovative Nano-Pulse Stimulation™ (NPS™) technology, which non-thermally clears unwanted cellular structures while preserving surrounding tissue. A controlled commercial launch will commence shortly with selected Key Opinion Leaders in the U.S., aiming for long-term commercial success.
Pulse Biosciences (Nasdaq: PLSE) has received CE mark approval for its CellFX® System, validating its Nano-Pulse Stimulation™ (NPS™) technology for treating dermatologic conditions like sebaceous hyperplasia and seborrheic keratosis in the EU. This marks the system's first commercial regulatory clearance, enabling a controlled launch in top aesthetic centers across Europe. The technology offers a unique approach to removing lesions without damaging adjacent tissue, presenting a significant advancement in aesthetic dermatology. The commercial launch is set to occur this quarter.
Pulse Biosciences (Nasdaq: PLSE) announced significant regulatory progress for its CellFX System. The FDA has moved its 510(k) submission for a general dermatology indication to Interactive Review. The company successfully completed treatments in a pivotal comparison study for sebaceous hyperplasia, with a 510(k) submission expected soon. Additionally, an FDA Investigational Device Exemption has been granted for a study on cutaneous non-genital warts. The review for CE mark approval and Health Canada license is also on track, showcasing robust advancements despite prior challenges.
Pulse Biosciences announced a notice of redemption for all outstanding warrants to purchase shares of the Company’s common stock, effective February 5, 2021. The redemption price is set at $0.01 per warrant. The warrants were issued as part of a rights offering that occurred in June 2020, which raised $30 million. The conditions for redemption were met as the average stock price exceeded $14.02 for ten consecutive trading days prior to December 31, 2020. If all warrants are exercised, the Company could receive an additional $4.5 million.
Pulse Biosciences (Nasdaq: PLSE) announced the grant of non-qualified stock options for 40,250 shares to recently hired non-executive employees on December 15, 2020. The options are priced at $18.40 per share, matching the closing stock price on the grant date, and will vest annually at 25% starting from the first anniversary of each recipient's start date. This grant is part of the 2017 Inducement Equity Incentive Plan, designed to attract new talent in accordance with Nasdaq rules.
Pulse Biosciences (NASDAQ:PLSE) is advancing its Nano-Pulse Stimulation™ (NPS™) technology, aimed at treating difficult skin lesions. A scientific update on NPS will feature at the upcoming Controversies and Conversations in Lasers & Cosmetic Surgery Symposium. Dr. Suzanne Kilmer will present clinical results demonstrating the safety and effectiveness of this technology. Over 700 patients and 3,600 lesions have been treated using NPS technology via the CellFX System. The company anticipates potential regulatory clearances in the U.S., EU, and Canada by Q1 2021, enhancing the prospects for commercialization.
Pulse Biosciences, Inc. (Nasdaq: PLSE) announces plans to participate in three upcoming virtual investor conferences. Management will present at the Stifel Healthcare Conference on November 17, 2020, and at the Stephens Annual Investment Conference on November 19, 2020. Additionally, they will engage in one-on-one meetings at the Piper Sandler Healthcare Conference on December 1, 2020, with a presentation webcast available on November 23, 2020. Interested parties can access webcasts from all conferences via the Company’s website, showcasing their innovative Nano-Pulse Stimulation™ technology.
Pulse Biosciences, Inc. (Nasdaq: PLSE) has announced it will release its third-quarter 2020 financial results on November 9, 2020, after market close. This announcement comes ahead of a scheduled conference call with management at 1:30 PM PT to discuss the results. The company is advancing its Nano-Pulse Stimulation™ (NPS™) technology, with the CellFX® System awaiting regulatory approval for commercial use in treating various dermatologic conditions. The technology aims to provide innovative solutions for patient care while offering a utilization-based revenue model.
Pulse Biosciences (Nasdaq: PLSE) announced positive clinical results from its Nano-Pulse Stimulation (NPS) technology at the ASDS virtual annual meeting held from October 9-11, 2020. The studies demonstrated effective treatment for sebaceous hyperplasia lesions, warts, and basal cell carcinoma using the CellFX System. Key findings included high clearance rates and improved patient satisfaction. The company has initiated a multicenter clinical study comparing NPS technology to RF electrodessication for sebaceous hyperplasia lesions, showcasing its commitment to dermatologic innovations.
Pulse Biosciences (Nasdaq: PLSE) announced FDA Investigational Device Exemption (IDE) approval for a pivotal study aimed at treating sebaceous hyperplasia (SH) lesions with its CellFX® System. This multicenter comparative study will enroll 60 patients to evaluate the safety and efficacy of the CellFX System against electrodessication. The first procedure took place on September 28, 2020. Results from this study will support a 510(k) submission to expand the CellFX indication for SH. The company aims to conclude the study by Q1 2021 and submit the 510(k) soon after.
FAQ
What is the current stock price of Pulse Biosciences (PLSE)?
What is the market cap of Pulse Biosciences (PLSE)?
